152 related articles for article (PubMed ID: 38757190)
21. How eluents define proteomic fingerprinting of protein corona on nanoparticles.
Qiu L; Zhang Y; Wei G; Wang C; Zhu Y; Yang T; Chu Z; Gao P; Cheng G; Ma A; Kwan Wong Y; Zhang J; Xu C; Wang J; Tang H
J Colloid Interface Sci; 2023 Oct; 648():497-510. PubMed ID: 37307606
[TBL] [Abstract][Full Text] [Related]
22. Protein-Nanoparticle Interaction: Corona Formation and Conformational Changes in Proteins on Nanoparticles.
Park SJ
Int J Nanomedicine; 2020; 15():5783-5802. PubMed ID: 32821101
[TBL] [Abstract][Full Text] [Related]
23. The interplay of quaternary ammonium lipid structure and protein corona on lung-specific mRNA delivery by selective organ targeting (SORT) nanoparticles.
Dilliard SA; Sun Y; Brown MO; Sung YC; Chatterjee S; Farbiak L; Vaidya A; Lian X; Wang X; Lemoff A; Siegwart DJ
J Control Release; 2023 Sep; 361():361-372. PubMed ID: 37536547
[TBL] [Abstract][Full Text] [Related]
24. Surface roughness influences the protein corona formation of glycosylated nanoparticles and alter their cellular uptake.
Piloni A; Wong CK; Chen F; Lord M; Walther A; Stenzel MH
Nanoscale; 2019 Dec; 11(48):23259-23267. PubMed ID: 31782458
[TBL] [Abstract][Full Text] [Related]
25. Uptake of Upconverting Nanoparticles by Breast Cancer Cells: Surface Coating versus the Protein Corona.
Voronovic E; Skripka A; Jarockyte G; Ger M; Kuciauskas D; Kaupinis A; Valius M; Rotomskis R; Vetrone F; Karabanovas V
ACS Appl Mater Interfaces; 2021 Aug; 13(33):39076-39087. PubMed ID: 34378375
[TBL] [Abstract][Full Text] [Related]
26. Impact of physicochemical properties on biological effects of lipid nanoparticles: Are they completely safe.
Yuan Z; Yan R; Fu Z; Wu T; Ren C
Sci Total Environ; 2024 Jun; 927():172240. PubMed ID: 38582114
[TBL] [Abstract][Full Text] [Related]
27. Influence of dynamic flow environment on nanoparticle-protein corona: From protein patterns to uptake in cancer cells.
Palchetti S; Pozzi D; Capriotti AL; Barbera G; Chiozzi RZ; Digiacomo L; Peruzzi G; Caracciolo G; Laganà A
Colloids Surf B Biointerfaces; 2017 May; 153():263-271. PubMed ID: 28273493
[TBL] [Abstract][Full Text] [Related]
28. Unleashing the Power of Proenzyme Delivery for Targeted Therapeutic Applications Using Biodegradable Lipid Nanoparticles.
Zheng Q; Ma T; Wang M
Acc Chem Res; 2024 Jan; 57(2):208-221. PubMed ID: 38143330
[TBL] [Abstract][Full Text] [Related]
29. Artificial engineering of the protein corona at bio-nano interfaces for improved cancer-targeted nanotherapy.
Khan S; Sharifi M; Gleghorn JP; Babadaei MMN; Bloukh SH; Edis Z; Amin M; Bai Q; Ten Hagen TLM; Falahati M; Cho WC
J Control Release; 2022 Aug; 348():127-147. PubMed ID: 35660636
[TBL] [Abstract][Full Text] [Related]
30. Distinct Proteins in Protein Corona of Nanoparticles Represent a Promising Venue for Endogenous Targeting - Part II: In vitro and in vivo Kinetics Study.
Sebak AA; Gomaa IEO; ElMeshad AN; Farag MH; Breitinger U; Breitinger HG; AbdelKader MH
Int J Nanomedicine; 2020; 15():9539-9556. PubMed ID: 33299308
[TBL] [Abstract][Full Text] [Related]
31. Protein Corona Formation on Lipid Nanoparticles Negatively Affects the NLRP3 Inflammasome Activation.
Debnath M; Forster J; Ramesh A; Kulkarni A
Bioconjug Chem; 2023 Oct; 34(10):1766-1779. PubMed ID: 37707953
[TBL] [Abstract][Full Text] [Related]
32. Modulating the toxicity of engineered nanoparticles by controlling protein corona formation: Recent advances and future prospects.
Wang J; Xu Y; Zhou Y; Zhang J; Jia J; Jiao P; Liu Y; Su G
Sci Total Environ; 2024 Mar; 914():169590. PubMed ID: 38154635
[TBL] [Abstract][Full Text] [Related]
33. The protein corona and its effects on nanoparticle-based drug delivery systems.
Li H; Wang Y; Tang Q; Yin D; Tang C; He E; Zou L; Peng Q
Acta Biomater; 2021 Jul; 129():57-72. PubMed ID: 34048973
[TBL] [Abstract][Full Text] [Related]
34. Effect of PEG Anchor and Serum on Lipid Nanoparticles: Development of a Nanoparticles Tracking Method.
Berger M; Degey M; Leblond Chain J; Maquoi E; Evrard B; Lechanteur A; Piel G
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839919
[TBL] [Abstract][Full Text] [Related]
35. Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis.
Qiu M; Tang Y; Chen J; Muriph R; Ye Z; Huang C; Evans J; Henske EP; Xu Q
Proc Natl Acad Sci U S A; 2022 Feb; 119(8):. PubMed ID: 35173043
[TBL] [Abstract][Full Text] [Related]
36. How protein coronas determine the fate of engineered nanoparticles in biological environment.
Capjak I; Goreta SŠ; Jurašin DD; Vrček IV
Arh Hig Rada Toksikol; 2017 Dec; 68(4):245-253. PubMed ID: 29337683
[TBL] [Abstract][Full Text] [Related]
37. Distinct Proteins in Protein Corona of Nanoparticles Represent a Promising Venue for Endogenous Targeting - Part I: In vitro Release and Intracellular Uptake Perspective.
Sebak AA; Gomaa IEO; ElMeshad AN; Farag MH; Breitinger U; Breitinger HG; AbdelKader MH
Int J Nanomedicine; 2020; 15():8845-8862. PubMed ID: 33204091
[TBL] [Abstract][Full Text] [Related]
38. Impact of Surface-Engineered ZnO Nanoparticles on Protein Corona Configuration and Their Interactions With Biological System.
Srivastav AK; Dhiman N; Khan H; Srivastav AK; Yadav SK; Prakash J; Arjaria N; Singh D; Yadav S; Patnaik S; Kumar M
J Pharm Sci; 2019 May; 108(5):1872-1889. PubMed ID: 30615879
[TBL] [Abstract][Full Text] [Related]
39. Recent Developments in the Design of Non-Biofouling Coatings for Nanoparticles and Surfaces.
Sanchez-Cano C; Carril M
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32028729
[TBL] [Abstract][Full Text] [Related]
40. Nano-Bio Interactions in Cancer: From Therapeutics Delivery to Early Detection.
Liu Y; Wang J; Xiong Q; Hornburg D; Tao W; Farokhzad OC
Acc Chem Res; 2021 Jan; 54(2):291-301. PubMed ID: 33180454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
